Impact of Validated Diagnostic Prediction Model of Acute Heart Failure in the Emergency Department
Analysis of the Impact of Using a Validated Diagnostic Prediction Model of Acute Heart Failure in the Emergency Department
Sponsor: Roche Pharma AG
A NA clinical study on Acute Heart Failure and Dyspnea, this trial is completed. The trial is conducted by Roche Pharma AG and has accumulated 6 data snapshots since 2010. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Oct 2021 — Jul 2024 [monthly]
Completed NA
-
Jan 2021 — Oct 2021 [monthly]
Completed NA
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed NA
First recorded
Sep 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Roche Pharma AG
- Unity Health Toronto
For direct contact, visit the study record on ClinicalTrials.gov .